Despite recent advances in therapeutic options, chronic viral infections, including infection with hepatitis C virus and hepatitis B virus, continue to be a significant cause of morbidity and mortality in Australia and affecting hundreds of millions of people worldwide. This R&D program aims to develop a cheaper drug formulation that is easier to deliver and more stable for transport to remote areas.
CHARACTERIZATION AND PURIFICATION OF A NOVEL ANTI-HIV FACTOR
Funder
National Health and Medical Research Council
Funding Amount
$170,810.00
Summary
We have identified biological evidence for a novel anti-HIV factor in a patient who has not progressed to HIV disease in 22 years. We have identified active forms in a solution, which confer potent activity against HIV. This factor helps in creating the pool of specialized antigen presenting cells, which are vital to combating with HIV in vivo. We propose to characterize this factor biologically, proteomically and genomically.